Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, announced today that it has been awarded $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases, including Progressive Supranuclear Palsy, Alzheimer’s Disease, and Fronto-temporal Dementia.
January 17, 2019
· 2 min read